Orrick advised Sosei Heptares. Sosei Heptares has announced its acquisition for U.S.$466 million (JPY 65 billion) of Idorsia’s pharmaceuticals business in Japan and APAC (ex-China). Sosei...
You must be a Standard 1 Year member to access this content.
Orrick advised Catalyst Biosciences, Inc. on the deal. South San Francisco-based biopharmaceutical company Catalyst Biosciences, Inc. announced its acquisition of the F351 program, a next-generation fibrosis drug,...
You must be a Standard 1 Year member to access this content.
Orrick Herrington & Sutcliffe advised Ipsen on the deal. Global biopharmaceutical company Ipsen (Euronext: IPN; ADR: IPSEY) announced its definitive agreement to acquire Epizyme (Nasdaq: EPZM), a...
You must be a Standard 1 Year member to access this content.
